Researchers have shown that inhibiting Treg activation in tumours can provide effective immune responses without autoimmune toxicity.
List view / Grid view
Filter the results
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.
Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.
New insights into the mechanisms of anti-OX40 antibodies could enable their therapeutic activity to be manipulated to treat different tumours.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
New research has provided a metabolic atlas for insights into obesity and tumours' ability to hide from the immune system.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
The scientists developed a therapy which uses nanobiologics to train the innate immune system to recognise and combat cancer cells.